JPMorgan analyst Rachel Vatnsdal lowered the firm’s price target on 10x Genomics (TXG) to $12 from $14 and keeps a Neutral rating on the shares ...

Stifel lowered the firm’s price target on 10x Genomics (TXG) to $18 from $21 and keeps a Buy rating on the shares. The funding environment ...

Biotech company 10x Genomics (NASDAQ:TXG) reported Q4 CY2024 results , but sales fell by 10.3% year on year to $165 million.

COPT Defense Properties offers a 4.2% dividend yield with high occupancy in defense real estate. Read my view on CDP stock.

The top five meme coins with 10x potential are gaining attention, especially during this market downturn, as investors look ...

Hop across to the best casinos and play the 333 Jolly Fat Frogs POWER COMBO online slot. It’s a bright and cheerful slot from ...

For the quarter ended December 2024, 10x Genomics (TXG) reported revenue of $165.02 million, down 10.3% over the same period last year. EPS came in at -$0.40, compared to -$0.41 in the year-ago ...

As of 2023 year-end, the firm had $1.2 billion of debt, $1.6 billion of cash and cash equivalents, and $1.5 billion of deferred taxes that are largely related to its Sartorius investment. We forecast ...

CEO Serge Saxonov, PhD, says provider of single cell, spatial, and in situ instruments expects to see benefits from sales reorganization and grow base of industry users.

Similar to the Rafale, the 10X has multiple control surfaces on the ... where having terrain and runway images directly in the pilot’s view could be indispensable. The cockpit features the ...

Nucor's stock is a buy with 4% boost and potential for 23% upside, supported by strong cash generation and trade policy benefits. Explore more details here.

Once bogged down by balance sheet stress and sluggish growth, many government-owned companies now stand on a firmer footing, ...